Drugs / AVX502
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT00706732 Comparator | Jun → Sep 2008 | influenza | AlphaVax, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00440362 Comparator | Apr → Sep 2007 | influenza | AlphaVax, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVX502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00706732 ↗ |
| Modality | Vaccine | “AVX502, an alphavirus replicon vaccine expressing an influenza HA protein” NCT00440362 ↗ |
| Route | Intramuscular | “via IM route” NCT00440362 ↗ |